Are the results of the SEAM-RA trial generalizable to other TNF inhibitors given the differences in immunogenicity?

This is a great question, and an important one because different TNF inhibitors have different immunogenicity and patients can make anti-drug antibodies that can effectively neutralize the drug and render it a less effective treatment option. This tends to happen more with some molecular constructs ...